KEY TAKEAWAYS
- The study aimed to comprehensively investigate MNDA expression across a sizable cohort of B-NHLs to assess its diagnostic significance.
- MNDA’s differential diagnostic potential in MZL, RLH, and FL contrasts with its limited utility in distinguishing MCL and CLL/SLL.
MNDA, or myeloid nuclear differentiation antigen, is proposed as a diagnostic marker for marginal zone lymphoma (MZL). However, its effectiveness in differentiating MZL from other B-NHLs and its clinicopathological significance in DLBCL remains unclear.
Li-Fen Zhang and the team aimed to comprehensively examine MNDA expression across a substantial collection of B-NHLs and assess its diagnostic significance.
The study assessed MNDA expression via immunohistochemistry in a cohort of 1293 B-NHL cases and 338 cases of reactive lymphoid hyperplasia (RLH). MNDA expression levels were then compared across various B-NHL subtypes. Additionally, the clinicopathological significance of MNDA in DLBCL was explored.
The results revealed that the MNDA exhibited high expression levels in MZLs (65.9%), contrasting with confined staining in marginal zone B-cells in RLH. Notably, neoplastic cells with plasmacytic differentiation showed a loss of MNDA expression.
MNDA expression was notably elevated in mantle cell lymphoma (MCL) at 79.6%, whereas it was lower in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) at 44.8%, lymphoplasmacytic lymphoma (LPL) at 25%, and markedly lower in follicular lymphoma (FL) at 5.2%, compared to MZL.
In DLBCL, 29.6% of cases were positive for MNDA. The non-GCB group displayed a higher rate of MNDA positivity (39.8%) than the GCB group (16.3%). Moreover, MNDA staining was more frequent in DLBCL cases with BCL2/MYC double-expression (50%) than in those without (24.8%). Additionally, a significant correlation between MNDA and CD5 expression was observed in DLBCL.
The findings indicated that MNDA shows significant expression in MZL, suggesting its potential as a diagnostic marker distinguishing MZL from RLH and FL. However, its utility in discriminating MZL from MCL and CLL/SLL is limited. Furthermore, MNDA expression is notably higher in non-GCB DLBCL and the BCL2/MYC double-expression group, correlating with CD5 expression.
Further investigation is needed to elucidate MNDA’s clinical relevance and correlation with lymphoma prognosis.
Funding was not applicable.
Source: https://pubmed.ncbi.nlm.nih.gov/38627702/
Zhang LF, Zhang Y, Shui RH, et al. (2024) “MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases.” Diagn Pathol. 2024 Apr 16;19(1):60. doi: 10.1186/s13000-024-01481-6. PMID: 38627702; PMCID: PMC11020995.
